RxDoctor Payments Data

Cletus Iwuagwu, MD

Geriatric Medicine · Toledo, OHNPI 1972598530

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $283 of the $355 with a category attached, or 79.8%. 7 manufacturers reported payments, led by Teva Pharmaceuticals USA, Inc. at 57.1% of the total. Reporting peaked in 2019 at $229 and has fallen 81.7% since, to $42 in 2025.

$355in general payments, 2019–2025

Across 11 payments — averaging $32.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$203
  • Otsuka America Pharmaceutical, Inc.$65
  • Lundbeck LLC$23
  • Neurocrine Biosciences, Inc.$21
  • Sunovion Pharmaceuticals Inc.$16
  • Dynavax Technologies Corporation$16
  • plus $11 from 1 others
$23in research payments, 2019–2025

Across 1 payment — averaging $23.35 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Merck$23

What the payments were for

  • Food & beverage$28380%
  • Education$7120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$355 in reported general payments places this provider in the 65th percentile of 146 geriatric medicine providers in Ohio.

See all geriatric medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$158,749
Medicare patients
389
Services billed
1,552

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban742$267,236
JardianceEmpagliflozin107$41,678
XareltoRivaroxaban130$41,130
JanuviaSitagliptin Phosphate61$26,937
RytaryCarbidopa/Levodopa31$23,341
GlatopaGlatiramer Acetate13$23,096
MyrbetriqMirabegron60$22,654
Atorvastatin Calcium1,214$21,453
TrulicityDulaglutide21$16,746
Breo ElliptaFluticasone/Vilanterol38$15,802
Rivastigmine77$15,649
Potassium Chloride527$15,071
NamzaricMemantine Hcl/Donepezil Hcl27$14,939
EntrestoSacubitril/Valsartan25$12,935
OzempicSemaglutide12$12,309

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$11$16,74621 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 146 geriatric medicine providers in Ohio.

Other geriatric medicine in Toledo

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →